BTK and myeloid sarcoma: Evobrutinib, a selective BTK inhibitor, was shown in a Phase II clinical trial for patients with relapsing MS to decrease the number of enhancing lesions vs. placebo (NCT02975349), although the relapse rate and disability progression did not differ between the two groups (Montalban et al., 2019).